Results 121 to 130 of about 5,986,727 (281)

Circulating tumor DNA monitoring and blood tumor mutational burden in patients with metastatic solid tumors treated with atezolizumab

open access: yesMolecular Oncology, EarlyView.
In patients treated with atezolizumab as a part of the MyPathway (NCT02091141) trial, pre‐treatment ctDNA tumor fraction at high levels was associated with poor outcomes (radiographic response, progression‐free survival, and overall survival) but better sensitivity for blood tumor mutational burden (bTMB).
Charles Swanton   +17 more
wiley   +1 more source

ÐšÐ»Ð¸Ñ€ÐµÐ½Ñ Ð½Ð° I-131 и Ts-99 во тиреоидеа кај Ñтаорец

open access: yes, 2017
Thyroid clearance of J-131 and Tc-99m after simultaneous subcutaneous injection in rats were estimated in the early phase. Arterial blood samples were drawn with a polyethene catheter inserted in the iliac artery in intervals of two minutes.
Таџер (Tadzher), ИÑак (Isak)   +1 more
core  

Dose‐dependent induction of epithelial‐mesenchymal transition in 3D melanoma models by non‐thermal plasma treatment

open access: yesMolecular Oncology, EarlyView.
Non‐thermal plasma treatment of melanoma cells induced epithelial‐mesenchymal transition (EMT) in a dose‐dependent fashion. This report highlights the critical need to further investigate potential adverse effects of non‐thermal plasma for cancer therapy and to optimize treatment parameters for clinical translation. Despite the promising results of non‐
Eline Biscop   +10 more
wiley   +1 more source

Проценка на ризик за безбедноÑта на водата за пиење и водоÑнабдувањето во КичевÑкиот регион за периодот од 1996-2013 година

open access: yes, 2017
Intensification of systemic chemotherapy with in- clusion of high doses methotrexate (MTX) has contributed to the improvement of event-free survival in children with acute lymphoblastic leukemia (ALL). Despite this benefit, this agent might cause serious
ЕфтимијадоÑка (Eftimijadoska), Фани (Fani)
core  

Molecular imaging predicts trastuzumab‐deruxtecan (T‐DXd) response in head and neck cancer xenograft models

open access: yesMolecular Oncology, EarlyView.
Trastuzumab‐deruxtecan, a HER2‐targeting antibody‐drug conjugate, shows promising antitumor activity in head and neck squamous cell carcinoma with low HER2 expression. In vitro and in vivo studies demonstrated dose‐dependent cell death and tumor growth reduction in low HER2‐expressing cell lines, which correlated with drug accumulation measured using a
Abdullah Bin Naveed   +8 more
wiley   +1 more source

D. Seifried, N. Stark: Energiedienstleistungen

open access: yesTechnikfolgenabschätzung – Theorie und Praxis, 1994
TATuP editorial office
doaj   +1 more source

Home - About - Disclaimer - Privacy